Lyell Immunopharma (LYEL) Projected to Post Earnings on Wednesday

Key Points

• Lyell Immunopharma is set to announce its Q2 2025 earnings on August 6th, with expectations of a loss of $0.19 per share.
• The company's last earnings report showed a loss of $3.60 per share, which exceeded analyst expectations by $0.20.
• Recently, Acadian Asset Management increased its stake in Lyell Immunopharma by 204.2%, owning approximately 66.05% of the company's stock as of the latest report.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Lyell Immunopharma to post earnings of ($0.19) per share for the quarter.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($3.60) EPS for the quarter, topping analysts' consensus estimates of ($3.80) by $0.20. The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 514,649.22% and a negative return on equity of 73.66%. On average, analysts expect Lyell Immunopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lyell Immunopharma Stock Performance

LYEL stock traded down $0.79 during trading on Friday, reaching $11.02. 19,787 shares of the company were exchanged, compared to its average volume of 72,573. The company has a market cap of $163.21 million, a P/E ratio of -0.44 and a beta of -0.19. Lyell Immunopharma has a 52-week low of $7.65 and a 52-week high of $32.40. The stock's 50 day moving average price is $9.91 and its 200 day moving average price is $10.45.

Analysts Set New Price Targets

A number of research firms recently commented on LYEL. HC Wainwright reissued a "neutral" rating and set a $10.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, June 24th. Wall Street Zen raised shares of Lyell Immunopharma to a "hold" rating in a report on Friday, June 6th.

Institutional Trading of Lyell Immunopharma

An institutional investor recently raised its position in Lyell Immunopharma stock. Acadian Asset Management LLC increased its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 204.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 660,899 shares of the company's stock after buying an additional 443,614 shares during the period. Acadian Asset Management LLC owned about 0.22% of Lyell Immunopharma worth $354,000 as of its most recent SEC filing. Institutional investors and hedge funds own 66.05% of the company's stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.